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Abstract
Although mounting evidence indicates the involve-
ment of galectin-3 in cancer progression and meta-
stasis, the underlying molecular mechanisms remain 
largely unknown. In this study, we investigated the ef-
fect and possible mechanism of galectin-3 on the mi-
gration and invasion of B16F10, a metastatic melano-
ma cell line, in which galectin-3 and matrix metal-
loproteinase-1 (MMP-1) were both found to be highly 
expressed. Knockdown of galectin-3 with specific 
siRNA reduced migration and invasion, which was as-
sociated with reduced expression of MMP-1. To further 
investigate the underlying mechanism, we examined 
the effect of galectin-3 knockdown on the activity of 
AP-1, a transcriptional factor regulating MMP-1 
expression. We found that galectin-3 directly inter-
acted with AP-1 and facilitated the binding of this com-
plex to the MMP-1 promoter that drives MMP-1 
transcription. Moreover, silencing of galectin-3 in-
hibited binding of fra-1 and c-Jun to promoter sites of 
MMP-1 gene. Consistent with these in vitro findings, 
our in vivo study demonstrated that galectin-3 shRNA 
treatment significantly reduced the total number of 
mouse lung metastatic nodules. Taken together, ga-
lectin-3 facilitates cell migration and invasion in mela-
noma in vitro and can induce metastasis in vivo, in part 
through, regulating the transcription activity of AP-1 
and thereby up-regulating MMP-1 expression. 
Keywords: galectin 3; matrix metalloproteinase 1; mel-
anoma; neoplasm metastasis; RNA, small interfering; 
transcription factor AP-1 
Introduction
Galectin-3, a chimera-type of 31-kDa galactose- 
binding protein, is highly expressed in a variety of 
primary and metastatic tumors (Raz et al., 1990). 
Galectin-3 is associated with enhanced tumor 
progression, invasion and metastasis in various 
cancer cells, e.g., lung and gastric cancer cells 
(Hood and Cheresh, 2002; Liu and Rabinovich, 
2005). Changes in circulating galectin-3 levels in 
cancer patients may reflect the metastatic spread of 
disseminating cancer cells (Yu, 2010). Thus, 
inhibition of galectin-3 may be a novel therapeutic 
approach for preventing metastasis and reducing 
cancer-associated mortality (Kim et al., 2010). 
However, the mechanisms underlying the role of 
galectin-3 in tumor progression and metastasis 
remain largely unclear. 
    Matrix metalloproteinases (MMPs) facilitate tumor 
progression and metastasis (Khokha, 1994; Ahonen 
et al., 1998; Valente et al., 1998). Among these, 
MMP-1, MMP-2, MMP-9 and MT1-MMP are involved 
in human melanoma invasion (Walker and Woolley, 
1999; Hofmann et al., 2005). MMP-1, which is 
capable of degrading type I, II and III collagens, is 
the only MMP subtype able to degrade triple helical 
collagens (Pardo and Selman, 2005). Recent 
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Figure 1. Expression levels of ga-
lectin-3 and MMP-1 in several 
mouse cell lines. (A) mRNA and (B) 
protein expression levels of ga-
lectin-3 and MMP-1 in B16F10, 
4T-1,TC-1 and NIH3T3 cell lines, 
determined by RT-PCR and western 
blotting. β-actin was used as a load-
ing control. (C) mRNA and (D) pro-
tein expression levels of galectin-3 
and MMP-1 in B16F1 and B16F10 
cell lines were determined by 
RT-PCR and western blotting. β-ac-
tin was used as normalization 
control.
studies showed that MMP-1 knockdown cells 
reduce melanoma invasion into matrigel, whereas 
its activation promoted melanoma cell invasion into 
three dimensional type I collagen (Durko et al., 
1997; Benbow et al., 1999). Clinical studies have 
also provided evidence that MMP-1 is positively 
correlated with malignancy of melanoma cells and 
poor prognosis of patients (Nikkola et al., 2002).
    MMP-1 expression is controlled by mitogen 
activated protein kinase (MAPK) pathway(s) and the 
upstream transcription factor, activation of activator 
protein-1 (AP-1) (Tower et al., 2003; Jung et al., 
2008). Although increasing attention has been paid 
to the roles of galectin-3 and MMP-1 in cancer 
metastasis, and a recent study showed a significant 
role of galectin-3 in MMP-1 expression in gastric 
cancer cells (Cheong et al., 2010; Cho et al., 2011; 
Kim et al., 2011), it is unclear whether similar 
regulation occurs in melanoma. 
    In this study, we demonstrated that galectin-3 
regulated MMP-1 expression and melanoma cell 
metastasis using B16F10 cell line, as a highly 
expression of both galectin-3 and MMP-1 in a 
mouse melanoma cell line. The B16F10 cell line is 
well established in in vivo mouse lung metastasis 
systems (Nguyen et al., 2007). We demonstrated 
that knockdown of galectin-3 reduced MMP-1 
expression and melanoma metastasis both in vitro 
and in vivo, in part by modulating AP-1 activity.
Results 
Expression levels of galectin-3 and MMP-1 in mouse 
cancer cell lines
The mRNA and protein expression of galectin-3 and 
MMP-1 were assessed in the following 4 cell types: 
highly metastatic melanoma cancer cell (B16F10), 
highly metastatic breast cancer cell (4T-1), HPV 
positive and invasive mouse cervical cancer cells 
(TC-1), and mouse fibroblast cells (NIH3T3). As 
shown in Figures 1A and 1B, galectin-3 was highly 
expressed in all four cell lines, whereas the 
expression of MMP-1 was obviously higher in the 
B16F10 cell line than in others. Compared to the 
non-metastatic cell line B16F1, B16F10 cells 
express a higher level of both galectin-3 and MMP-1, 
in both mRNA and protein levels, respectively 
(Figures 1C and 1D).
Galectin-3 knockdown inhibited B16F10 melanoma 
cell migration and invasion 
To examine the effects of galectin-3 knockdown on 
B16F10 cell migration and invasion, cells were 
transfected with various concentrations of galectin-3 
siRNA, and galectin-3 expression was assessed 
using real time PCR and western blotting 
respectively. As shown in Figure 2A, all three 
concentrations of galectin-3 siRNA significantly 
reduced protein expression, with no significant 
differences in potency. Thus, 20 nM of galectin-3 
was chosen for the following experiments. After 
transfection of B16F10 cells with 20 nM galectin-3 
siRNA for 24 h, the living cells were collected and 
subjected to wound healing, invasion and migration 
assays. As shown in Figure 2B, cells transfected 
with galectin-3 siRNA migrated significantly slower 
than those without transfection or transfected with a 
scRNA in wound healing assays. Representative 
images are shown in Figure 2C. In addition, our 
trans-well migration and invasion assays also 
demonstrated approximately 50% and 65% decrease 
in cell migration and invasion, respectively, in the 
galectin-3 siRNA transfected cells compared to the 
control cells (Figures 2D and 2E). 
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Figure 2. Effect of galectin-3 silencing on the migration and invasion of 
B16F10 melanoma cells. (A) mRNA and protein levels of galectin-3 after 
transfection of B16F10 melanoma cells with different concentrations (10, 
20, 30 nmol/L) of scrambled siRNA (scRNA, negative control) and ga-
lectin-3 siRNA. Total RNA and protein were obtained after transfection for 
48 h, and cells were harvested and analyzed by real time-PCR and west-
ern blotting, respectively. β-actin was used as a loading control. (B-C) A 
wound healing assay of B16F10 cells was performed with scRNA or ga-
lectin-3 siRNA at 0, 12, 18 and 24h after scratching. (B) Quantification of 
cell migration as described in the Methods section and (C) the micro-
graphs of B16F10 cells were obtained according to the width change of 
the area lacking cells (Bar = 100 μm). (D-E) Cell migration and invasion 
activities were measured respectively by a Transwell assay after trans-
fection of melanoma cells with scRNA or galectin-3 siRNA for 24 h. All 
experiments were performed individually in triplicate (P＜ 0.001 vs. con-
trol group).
Galectin-3 modulated MMP-1 expression through 
interacting with AP-1
Given the expressions of both galectin-3 and 
MMP-1 in the mouse B16F10 cell line, we examined 
their possible interactions and the effect of MMP-1 
on cell motility. MMP-1 knockdown had no effect on 
the expression of galectin-3，but galectin-3 knock-
down resulted a marked reduction of MMP-1 
expression, indicating that galectin-3 is an upstream 
regulator of MMP-1 (Figure 3A). A cell proliferation 
assay demonstrated that transfection of gal-3 
siRNA or MMP-1 siRNA slightly decreased cell 
proliferation compared to the scrambled siRNA 
transfected cells (Figure 3B). In contrast, MMP-1 
knockdown dramatically decreased cell motility 
(Figures 3C and 3D). To further explore how 
galectin-3 increases MMP-1 expression in melanoma 
cells, we focused on the transcription factor, activator 
protein-1 (AP-1), which is a dimer composed of Jun 
and Fos-like region antigen (Fra-1) (Angel and 
Karin, 1991). The direct interaction between galectin-3 
and members of AP-1, c-Jun and Fra-1 was 
demonstrated by immunoprecipitation (Figure 3E). 
Next, we assessed transcription activity of AP-1 
using a luciferase assay. Compared to the control 
cells, transfection of the cells with galectin-3 shRNA 
significantly reduced AP-1 transcription activity 
(Figure 3F). Finally, we examined DNA binding 
activity of AP-1 with or without galectin-3. Figure 3G 
shows the binding site of the AP-1 complex on the 
MMP-1 promoter region. Our ChIP assay demon-
strated that c-jun and fra-1 bound to the promoter 
regions of MMP-1 in the presence, but not in the 
absence, of galectin-3 (Figure 3H). 
Galectin-3 knockdown decreased B16F10 
metastasis in lung metastasis mouse models
We constructed lentiviral vectors containing lacZ 
(negative control) or galectin-3 shRNA, and infected 
B16F10 cells with the lentivirus. As shown in Figure 
4A, transfection of the B16F10 cells with galectin-3 
siRNA resulted in approximately 53% reduction of 
the mRNA level of the target protein. As expected, 
transfection of B16F10 cells with galectin-3 markedly 
reduced the expression of MMP-1 (Figure 4B). To 
examine the effect of galectin-3 knockdown on 
melanoma metastasis in vivo, we applied the 
lentiviral infected cells to a mouse pulmonary 
metastasis model. Metastasis was assessed in 
C57BL/6 mice four weeks after tail vein injection of 
B16F10 parent cells, B16F10 cells infected with 
lentiviral lacZ, or gal-3shRNA. As shown in Figures 
4C and 4D, the total numbers of lung metastatic 
nodule were reduced by approximately 50% in the 
animals injected with the B16F10 cells containing 
lentiviral gal-3 shRNA compared to the animals 
injected with B16F10 parent cells or lacZ expressing 
B16F10 cells. 
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Figure 3. Effect of galectin-3 on MMP-1 expression through binding with 
AP-1 complex and effect of MMP-1 silencing on the motility of B16F10 mela-
noma cells. (A) mRNA and protein expression levels of galectin-3 or MMP-1
were detected by RT-PCR and western blotting respectively after trans-
fection of B16F10 melanoma cells with galectin-3 or MMP-1 siRNA. scRNA
was used as negative control and β-actin was used as a loading control. (B)
Cell proliferation was detected after transfection of B16F10 cells with 
scrambled siRNA, galectin-3 siRNA or MMP-1 siRNA for 24 and 40 h by 
MTT assay as described in the Methods section ( *P＜ 0.001, **P＜
0.001, ◦P＜ 0.001, ◦◦P＜ 0.001). (C, D) Wound healing assays utiliz-
ing B16F10 melanoma cells were performed by scRNA or MMP-1 siRNA 
transfected cells at 0, 12, 18 and 24 h after creating a scratch. (C) The phase
micrographs of B16F10 cells were obtained according to the data. (bar=100
μm) and (D) quantification of cell migration using the monolayer wound 
healing assay was performed as described in the Methods section. All ex-
periments were performed individually in triplicate. (E) Interaction between 
galectin-3 and AP-1 (Fra-1 and c-Jun) was measured by im-
munoprecipitation as previously described in “Methods”, and then ex-
pression of galectin-3, Fra-1 and c-Jun was detected by western blot. 
Whole-cell lysates (WCLs) were used as a positive control. (F) Luciferase 
activity of AP-1 in lacZ and galectin-3 knock down cells. Luciferase assay 
was performed using an AP-1 expression luciferase vector transfection to 
lacZ and galectin-3 knock down cells (P＜ 0.01, vs. Cont). (G) The prox-
imal AP-1 binding site which is located between -80 and -68 from the ini-
tiation codon of the MMP-1 gene. (H) A ChIP assay was performed using an-
tibodies against galectin-3, c-Jun and Fra-1 in melanoma cells transfected
with scRNA and galectin-3 siRNA. In the input lane, total genomic DNA was
used as a control for the PCR reaction.
Figure 4. Suppressive effects of galectin-3 silencing on metastasis of 
B16F10 melanoma cells in lung metastasis mouse models. (A) 
Expression levels of galectin-3 were detected by real time-PCR analysis 
in B16F10 cells infected with lenti-virus expressing LacZ or galectin-3 
shRNA (gal-3shRNA). The preparation and infection of these lenti-vi-
ruses were described in the Methods section. (B) Expression levels of 
galectin-3 and MMP-1 were detected by RT-PCR and western blot analy-
sis in B16F10 melanoma cells transfected stably with lacZ and 
gal-3shRNA respectively. β-actin was used as a loading control. (C, D) 
Four weeks after tail vein injection of PBS (negative control), parent 
B16F10 melanoma cells, lacZ expressing B16F10 cells or gal-3shRNA 
expressing cells into C57BL/6 mice, the formation of lung colonies was 
counted and illustrated as a histogram (P＜ 0.01 vs. lacZ group) (C) 
and photographs (D). The details are described in the Methods section.
Discussion
This study was performed to better understand the 
mechanisms underlying the role of galectin-3 in 
melanoma invasion and metastasis. We have 
previously shown that after silencing of galectin-3, 
some genes such as MMP-1 and MMP-3 are 
down-regulated , while other genes, such as serine 
protease inhibitor and tissue inhibitors of MMP-2 
were up-regulated (data not shown) (Cheong et al., 
2010). Among these genes, MMP-1 was down- 
regulated by galectin-3 to a greater extent than 
others, which was further confirmed by the following 
findingsWe confirmed the extensive expression of 
galectin-3 in different mouse cell lines including 
B16F1, B16F10 (melanoma), 4T-1 (breast carcinoma), 
TC-1 (lung cancer) and NIH3T3 (embryonic 
fibroblast), which may imply its conservation and 
significance in many types of cancer. However, 
much higher expression of MMP-1 was detected in 
the melanoma cell line B16F10 than in the 4T-1, 
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TC-1 and NIH3T3 cell lines. We also assessed 
galectin-3 and MMP-1 expression in the B16F1 and 
B16F10 melanoma cell lines and found that the 
non-metastatic cell line (B16F1) did not express 
galectin-3 while the metastatic cell line (B16F10) 
did. A previous report indicated that galectin-3 
regulates the metastasis of various types of cancer 
via different mechanisms (Liu and Rabinovich, 2005). 
However, the mechanisms underlying the involvement 
of galectin-3 in mouse cancer cell motility remain 
largely unknown. Our findings seem to indicate that 
one possible mechanism of melanoma cell motility 
in mice involves a putative relationship between 
galectin-3 and MMP-1 expression. 
    We observed that galectin-3 knockdown drama-
tically suppressed the motility, migration, and 
invasion of melanoma cells. In parallel, MMP-1 
knockdown also significantly reduced the cell 
motility. Knockdown of galectin-3 reduced the 
expression of MMP-1 but not vice versa, and it is 
suggested that galectin-3 is an upstream regulator 
of MMP-1. This finding sheds new light on the 
mysterious relationships between galectin-3 and 
MMP-1. To understand how galectin-3 regulates 
MMP-1 expression, we determined the interaction 
between galectin-3 and the AP-1 complex (Song et 
al., 2005). The AP-1 family of transcription factors is 
composed of the homodimers or heterodimers of 
the Jun (JunB, JunD, c-Jun) and Fos (c-Fos, Fos B, 
fra-1, fra-2) onco-proteins (Lee et al., 1987). Among 
them, c-Jun plays important roles in regulating 
cancer invasion and metastasis. For instance, the 
c-Jun dominant-negative mutant, TAM67, inhibits the 
effects of AP-1 on the growth of breast cancer 
(Moore-Carrasco et al., 2006), as well as on the 
invasion and metastasis of murine osteosarcomas 
(Leaner et al., 2009). Fra-1, another component of 
the AP-1 family, plays a key role in MMP-1 
transcription in A2058 melanoma cells (Tower et al., 
2003). Here, we provide evidence for the association 
of galectin-3 with c-Jun and fra-1 and regulation of 
AP-1 transcription activity. Interestingly, c-Jun and 
fra-1 bound to the promoter regions of MMP-1 in the 
presence of galectin-3, but not in its absence. This is 
the first case reported in which galectin-3 
contributes to MMP-1 promoter activity by forming a 
complex with c-Jun and fra-1 in melanoma cells. 
The role of galectin-3 in melanoma metastasis was 
also supported by the in vivo experimental results. 
In a mouse pulmonary metastasis model, animals 
treated with galectin-3 shRNA-transfected B16F10 
melanoma cells showed considerable inhibition of 
lung metastasis compared with the untreated 
control group.
    In conclusion, the promotion of galectin-3 expression 
resulted in melanoma invasion/metastasis due at 
least in part to increased MMP-1 expression via the 
transcriptional activation of AP-1. These findings 
combined with the recent report by Kim et al, for the 
involvement of galectin-3 in gastric cancer cell 
motility (Kim et al., 2011), suggest that galectin-3 
plays a role in various cancers’ metastasis through a 
common molecular mechanism. 
Methods
Cell culture and siRNAs transfection 
B16F1, B16F10, 4T-1, TC-1 and NIH3T3 cell lines ob-
tained from the Korea Cell Line Bank were cultured in 
DMEM or RPMI 1640 medium with 5% fetal bovine serum 
(FBS) and 1% Antibiotics (Invitrogen). Both galectin-3 and 
MMP-1 siRNAs were purchased from Invitrogen and trans-
fection was performed with Lipofectamine RNAiMAX re-
agent (Invitrogen) following the manufacturer’s instructions. 
The sequences of mouse galectin-3 and MMP-1 siRNAs 
were 5'-AUGAUUGUGAUCAGCAUGCTT-3' and 5'-GCCA 
GAACTTCCCAACCAT-3', respectively.
RNA isolation and RT-PCR
Total RNA was extracted from mouse melanoma cells with 
TRIzol reagent (Invitrogen) according to the manufacturer’s 
protocol. RT was carried out using a Reverse Transcription 
system (Promega), and PCR was performed with Ex-taq 
DNA polymerase (TaKaRa). The sequences of primers were 
as follows: mMMP-1; 5'-CCTGGAATTGGCAACAAAGT-3' 
(sense) and 5'-TAGCACGCAAGAATCAGGTG-3' (anti-sense); 
mGalectin-3: 5'-CAGTGCTCCTGGAGG CTATC-3' (sense) 
and 5'-AAGGGGAAGGCTGACTGTCT-3' (anti-sense); mβ- 
actin: 5'-AGCCTCGCCTTTGCCGA-3' (sense) and 5'-CTG 
GTGCCTGGGGCG-3' (anti-sense). 
Western blot analysis
Western blot analysis was carried out as described pre-
viously (Kim et al., 2010). Briefly, cells were lysed in RIPA 
buffer (Biosesang) containing a protease inhibitor cocktail 
(Sigma), followed by sonication on ice. The cell lysate was 
centrifuged and the supernatant was collected. Twenty μg 
of proteins were subjected to SDS-PAGE and transferred 
to PVDF transfer membranes (Amersham). After being 
blocked with 5% skim milk for 1 h, the membrane was in-
cubated with primary antibody dissolved in 5% BSA over-
night at 4oC. The membrane was then incubated with sec-
ondary antibody for 1 h, followed by detection with an ECL 
kit (Amersham). The following antibodies were used: an-
ti-β-actin (Santa Cruz); anti-galectin-3 (Santa Cruz); an-
ti-MMP-1 (Calbiochem, Santa Cruz). 
Immunoprecipitation assays
Cell lysate containing 750 μg of protein was pre-cleared by 
incubation with 40 μl protein-A/G linked agarose beads 
(Santa Cruz) for 1 h at 4oC. After the beads were spun 
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down, the supernatant was incubated with 1 μg specific an-
tibody (anti-galectin-3, anti-c-Jun and anti-Fra-1, respectively) 
overnight at 4oC, followed by incubation with 40 μl pro-
tein-A/G agarose beads for 1 h. Mouse/rabbit IgG (Santa 
Cruz) was used as the negative control. After the in-
cubation, beads were washed 3 times in RIPA buffer be-
fore being dissolved in SDS-PAGE loading buffer. Western 
blot analysis was performed as described above. 
Transfilter migration and invasion assays 
Transfilter migration and invasion assays were carried out 
with 8.0-μm pore inserts in 24-well Transwells (Corning 
Costar). Briefly, B16F10 cells were transfected with ga-
lectin-3 or MMP-1 siRNAs. One day after the transfection, 
cells were isolated and added to upper Transwell cham-
bers with 0.5 mg/ml collagen type I (BD Bioscience) coated 
filters for the migration assay, and with 1/15 dilution of ma-
trigel (BD Bioscience) coated filters for the invasion assays. 
DMEM containing 10% FBS and 1% antibiotics was added 
to the lower chamber and incubation continued for 20 h. 
Cells that had migrated or invaded into the lower chamber 
were quantified after H&E staining. For quantification, cells 
on were counted at 5 randomly selected areas in each well 
using a wide-field microscopy. Data were expressed as 
mean ± SD from three independent experiments.
Wound healing assays
B16F10 cells were seeded into 6-well culture dishes at 1×
105 cells/well, and maintained in DMEM containing 5% 
FBS for 24 h. The nearly confluent cells were scratched 
with a pipette tip and cellular debris was removed. The 
scratched monolayer was then incubated for another 24 h 
in DMEM. Cells migrating into the gap were visualized and 
counted under a microscope. 
Lentivial galectin-3 shRNA construction and stable 
cell line establishment
Lenti-viral vectors containing galectin-3 shRNA (Gal-3shRNA) 
was constructed by inserting the double strand gal-3 
shRNA into the lentiviral vector pLL3.7 as described pre-
viously (Kim et al., 2010). The sequence of the shRNA was 
as following: gal-3shRNA sense: 5'-TGAACAACAGGAGA 
GTCATTGTTTCAAGAGAACAATGACTCTCCTGTTGTTC
TTTTTTC-3'; gal-3shRNA antisense: 5'-TCGAGAAAAAA 
GAACAACAGGAGAGTCATTGTTCTCTTGAAACAATGAC
TCTCCTGTTGTTCA-3'. The lentiviral vector containing 
lacZ was used as a control. Lentiviral infection of B16F10 
melanoma cells was performed as described previously 
(Kim et al., 2010). Approximately 80% cells were infected 
and confirmed with FACS analysis. 
Mouse pulmonary metastasis model
Female C57BL/6 mice, purchased from Orient Bio in 
Korea, were maintained in the animal facility at the National 
Cancer Center (NCC). B16F10 cells (1×106 cells/ml in 
100 μl PBS) infected with lentiviral lacZ (control) or 
gal-3shRNA was injected into 6-week-old female C57BL/6 
mice (five mice per group) through the lateral tail vein. Four 
weeks after the injection, mice were sacrificed with an 
overdose of anesthesia. The number of metastatic nodules 
on the surface of the lung was counted under the surgical 
microscope.
Chromatin immunoprecipitation assay
A chromatin immunoprecipitation (ChIP) assay was carried 
out using a ChIP assay kit (Upstate). Samples were applied 
to dishes after galectin-3 siRNA treatment and assays 
were conducted following the manufacturer’s instructions. 
Anti-galectin-3, c-Jun and Fra-1 and normal mouse/rabbit 
IgG were used to immunoprecipitate DNA containing 
complexes. Prior to PCR, primers were prepared for AP-1 
with MMP-1 promoter binding sites: MMP-1 promoter 
(-2950) 5'-AAGAAGAAGGTGGCCAGGAT-3' and (-2901) 
5'-TGCCTTCATTT TCCATTTCC-3'. PCR was performed 
with Ex Taq (Takara).
Cell proliferation assay 
B16F10 cells, growing in 96-well culture plates at a density 
of 3× 103 cells/well，were transfected with scrambled 
siRNA, galectin-3 siRNA, and MMP-1 siRNA respectively. 
24 or 40-h post transfection, cell viability was analyzed by 
MTT assay, as described previously (Cheong et al., 2010). 
Luciferase assays 
B16F10 melanoma cell lines were co-transfected with an 
AP-1 reporter plasmid and galectin-3 siRNA 48 h before 
the luciferase assay was performed, as described pre-
viously (Kim et al., 2010). 
Statistics analysis
All data were obtained from at least three independent ex-
periments and are presented as mean ± SD, unless other-
wise indicated. Statistical analysis was performed using 
one-way ANOVA. Data were considered significant if P＜
0.05.
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